Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
WEBby Iqra Mumal, MSc July 8, 2019. An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
For PAH Treatment, Mylan Launches Tadalafil Tablets, 1st Generic...
WEBAug 22, 2018 · Mylan Announces U.S. Launch of 20 mg Tadalafil Tablets, 1st Generic of Adcirca for PAH Treatment. by Iqra Mumal, MSc August 22, 2018. Mylan recently introduced a formulation of 20 mg tadalafil tablets, the first generic version of Eli Lilly ‘s Adcirca, in the United States for patients with pulmonary arterial hypertension (PAH).
Airplane travel can be safe, manageable for PH patients: Study
WEBAug 26, 2024 · Airplane travel appears to be safe for people with pulmonary hypertension (PH) with both slight and marked limitations of physical activity, though some individuals may need oxygen support on board to help with breathing, according to a new study. While some patients in the study, dubbed PEGASUS (NCT03051763), experienced mild discomfort during ...
Yutrepia, Inhaled Treprostinil for PAH, Given Tentative Approval in …
WEBNov 10, 2021 · The U.S. Food and Drug Administration (FDA) has granted tentative approval to Yutrepia (treprostinil), previously known as LIQ861, as an inhalation treatment for pulmonary arterial hypertension (PAH), its developer Liquidia announced. Tentative approval means that Yutrepia has met all regulatory standards regarding quality, …
Tyvaso Becomes 1st PH-ILD Treatment Approved in US
WEBApr 1, 2021 · 462488992/Shutterstock. Tyvaso (inhaled treprostinil) has become the first treatment approved in the U.S. for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The U.S. Food and Drug Administration (FDA) approved Tyvaso, developed by United Therapeutics, to improve exercise ability in …
Macitentan-tadalafil combination therapy effective in PAH: Analysis
WEBAug 12, 2024 · For people with pulmonary arterial hypertension (PAH) both with and without a few co-occurring heart problems, combination therapy with macitentan and tadalafil is similarly effective, according to a new analysis by researchers in the U.S. and Europe. “Initial combination therapy with macitentan plus tadalafil is efficacious in patients with ...
FDA approves sotatercept, now Winrevair, to treat PAH in adults
WEBMar 27, 2024 · The now-approved treatment is expected to be available for dispensing by select U.S. specialty pharmacies by the end of April, according to Merck, which has owned the rights to the biologic therapy since acquiring prior developer Acceleron Pharma in 2021. Winrevair specifically is intended to enhance exercise capacity, improve World Health Organization (WHO) functional class, and reduce the ...
PAH Patients May Switch to Inhaled Treprostinil Without Harm...
WEBby Ana Pena, PhD February 10, 2020. Switching from injectable treprostinil or epoprostenol to a combination therapy including inhaled treprostinil appears to be safe, well tolerated, and effective for a select group of patients with clinically stable pulmonary arterial hypertension (PAH), a study suggests. The study, “ Ambulatory Transition ...
In PH, dilated pulmonary artery is common: Large-scale study
WEBby Steve Bryson, PhD January 3, 2024. Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature among people with pulmonary hypertension (PH) in a large-scale study. The clinical characteristics related to a dilated pulmonary artery, such as …
Winrevair approval favored to aid exercise in adults with PAH in EU
WEBJul 1, 2024 · The injectable medication was approved in the U.S. in March, where it is indicated to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening in adults with PAH.. As an activin signaling inhibitor, Winrevair works to block the activity of proteins implicated in the uncontrolled cell growth that causes blood vessels to narrow in PAH.